electroCore Inc ECOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ECOR is a good fit for your portfolio.
News
-
electroCore to Join Russell Microcap® Index
-
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
-
electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
-
Firefly Neuroscience, an AI-Driven Brain Health Company, Names Brian S. Posner to its Board of Directors, Upon Closing of Its Merger Transaction with WaveDancer
-
electroCore Announces First Quarter 2024 Financial Results
-
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
-
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
-
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
Trading Information
- Previous Close Price
- $6.34
- Day Range
- $6.04–6.32
- 52-Week Range
- $3.83–7.90
- Bid/Ask
- $6.00 / $7.10
- Market Cap
- $39.70 Mil
- Volume/Avg
- 4,461 / 11,135
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 62
- Website
- https://www.electrocore.com
Valuation
|
Metric
|
ECOR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.47 |
Price/Sales | 2.03 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ECOR
|
|---|---|
Quick Ratio | 1.06 |
Current Ratio | 1.50 |
Interest Coverage | — |
Quick Ratio
ECOR
Profitability
|
Metric
|
ECOR
|
|---|---|
Return on Assets (Normalized) | −90.00% |
Return on Equity (Normalized) | −177.52% |
Return on Invested Capital (Normalized) | −166.88% |
Return on Assets
ECOR
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Jjptkdk | Ylhlckk | $180.0 Bil | |||
| Stryker Corp
SYK
| Zjxvymhsjp | Yprr | $130.7 Bil | |||
| Boston Scientific Corp
BSX
| Cskzlwtxw | Kdsryf | $113.1 Bil | |||
| Medtronic PLC
MDT
| Sfkpswkd | Khxhtr | $107.1 Bil | |||
| Edwards Lifesciences Corp
EW
| Kxhmshqxq | Tpzcw | $52.8 Bil | |||
| DexCom Inc
DXCM
| Ldmrgxhp | Jww | $45.1 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Lfvpvkvm | Scbnrs | $24.5 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Rbwqjsjwrg | Nqlx | $22.0 Bil | |||
| Steris PLC
STE
| Nqfgkzxn | Stzpmp | $21.9 Bil | |||
| Align Technology Inc
ALGN
| Plllwzzkr | Nvgwmcb | $20.4 Bil |